Realtime-Estimate
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
25.72 USD | -0.41% | +8.50% | +93.31% |
Kurzporträt
Mitarbeiterzahl: 141
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Jason Rhodes
FOU | Founder | 54 | 01.12.17 |
Rick Scalzo
DFI | Director of Finance/CFO | 38 | 01.12.19 |
John Najim
CTO | Chief Tech/Sci/R&D Officer | 48 | 01.08.19 |
Chief Tech/Sci/R&D Officer | 63 | 27.01.20 | |
Chief Tech/Sci/R&D Officer | 61 | 28.06.19 | |
Wildon Farwell
CTO | Chief Tech/Sci/R&D Officer | 49 | 04.03.21 |
Ashish Dugar
CTO | Chief Tech/Sci/R&D Officer | - | 08.02.21 |
Susanna High
COO | Chief Operating Officer | 56 | 01.07.20 |
Amy Reilly
IRC | Investor Relations Contact | 51 | 01.07.20 |
Daniel Wilson
LAW | General Counsel | 53 | 01.06.20 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Edward Hurwitz
BRD | Director/Board Member | 60 | 01.11.18 |
David Lubner
BRD | Director/Board Member | 60 | 01.03.20 |
Dirk Kersten
BRD | Director/Board Member | 49 | 01.11.18 |
Jason Rhodes
FOU | Founder | 54 | 01.12.17 |
Carlo Incerti
BRD | Director/Board Member | 65 | 02.03.22 |
Chief Tech/Sci/R&D Officer | 61 | 28.06.19 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 86 177 719 | 85 700 570 ( 99,45 %) | 0 | 99,45 % |
Unternehmenskontakt
Sektor
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
+93.31% | 2.23 Mrd. | |
+19.04% | 42.68 Mrd. | |
-3.08% | 42.4 Mrd. | |
+45.32% | 40.04 Mrd. | |
-6.20% | 28.31 Mrd. | |
+7.11% | 24.94 Mrd. | |
-20.59% | 18.96 Mrd. | |
+30.21% | 12.3 Mrd. | |
-2.55% | 11.95 Mrd. | |
-2.89% | 11.55 Mrd. |
- Börse
- Aktien
- A2QB6B Aktie
- Unternehmen Dyne Therapeutics, Inc.